Lepu Medical: Subsidiary Shanghai Minwei Biotechnology Co., Ltd. signs an authorization License agreement and acquires 9.99% equity in Denmark's Sidera Bio Aps.

Lepu Medical announced that its controlling subsidiary, Shanghai Minwei Biotechnology Co., Ltd., will license the MWN105 injection with independent intellectual property rights to Denmark's Sidera Bio Aps for a fee. Denmark's Sidera company will obtain exclusive rights to develop and commercialize the product globally outside of Greater China. As part of the agreement, Shanghai Minwei Biotechnology will acquire a 9.99% stake in Denmark's Sidera company and will receive a licensing fee for the MWN105 injection. The licensed product MWN105 injection is a GLP-1/GIP/FGF21 receptor triple agonist developed independently by Shanghai Minwei Biotechnology, currently in the domestic clinical trial stage.